Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eftilagimod Alpha + NAC in HR+/HER2- Breast Cancer
NCT07102940Phase 2Not yet recruiting
- Sponsor
- George Washington University
- Start
- Sep 2026
- Primary completion
- Aug 2028
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of eftilagimod alpha in breast cancer, sponsored by George Washington University. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
eftilagimod alpha
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07102940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07102940.